Anxiety disorders

Penninx, Brenda W. J. H.; Pine, Daniel S.; Holmes, Emily A.; Reif, Andreas

doi:10.1016/s0140-6736(21)00359-7

Cited by 364 publications

(248 citation statements)

References 137 publications

Supporting

Mentioning

215

Contrasting

Unclassified

Order By: Relevance

“…Symptom severity in anxiety disorders has been linked to greater clinical burden, higher levels of comorbidity, and poorer treatment response [11]. Prior meta-analyses have highlighted the difference in QOL among individuals with clinical levels of anxiety symptoms compared to those without [6].…”

Section: Symptom Severitymentioning

confidence: 99%

Correlates of Quality of Life in Anxiety Disorders: Review of Recent Research

Wilmer

Anderson

Reynolds

2021

Curr Psychiatry Rep

View full text Add to dashboard Cite

Purpose of Review Anxiety disorders are highly prevalent conditions that have a detrimental impact on quality of life (QOL), particularly when left untreated. In the present review, we summarize recent literature, published within the last 3 years, on QOL in anxiety disorders, with a focus on factors that may play a role in the relationship between anxiety and QOL. Recent Findings We organize our findings into four categories: (1) subjective distress, (2) behavioral responses, (3) functional impairment, and (4) clinical factors. Results indicate that greater anxiety symptom severity is linked with poorer QOL, and cognitive behavioral therapies for anxiety yield positive effects on QOL. Additional transdiagnostic mechanisms are highlighted, including anxiety sensitivity, distress tolerance, emotion regulation, and avoidant coping. We examine the role of functional impairment, and we discuss factors related to treatment, including comorbidity and longitudinal effects. We also consider early research from the COVID-19 pandemic. Summary Understanding the underlying factors that contribute to QOL detriments provides important insight into the impact of anxiety disorders and identifies targets for enhancing QOL through treatment.

show abstract

Section: Symptom Severitymentioning

confidence: 99%

Correlates of Quality of Life in Anxiety Disorders: Review of Recent Research

Wilmer

Anderson

Reynolds

2021

Curr Psychiatry Rep

View full text Add to dashboard Cite

show abstract

“…Recently, with the continuous acceleration of the pace of life, the incidence of anxiety disorders is increasing. Currently, the first-line treatment of anxiety is benzodiazepines, but their long-term use can cause drug dependence and memory and cognitive impairment, increasing the risk of motor function damage and affecting its clinical application [ 3 ]. Traditional Chinese medicine has fewer side effects and strong individualization with high clinical research value [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Jie‐Yu‐He‐Huan Capsule Ameliorates Anxiety‐Like Behaviours in Rats Exposed to Chronic Restraint Stress via the cAMP/PKA/CREB/BDNF Signalling Pathway

Geng

et al. 2021

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Chronic stress is a critical factor in the aetiology of anxiety disorders; however, in the clinic, enduring and preventive measures are not available, and therapeutic drugs are associated with inevitable side effects. Our study established an anxiety rat model using chronic restraint stress (CRS) and assessed these animals using the open-field test, elevated plus-maze test, and light-dark box test. Jie-Yu-He-Huan capsule (JYHH), a Chinese medicine formula, was used as a preventative drug. The HPA axis-mediated release of corticotropin-releasing hormone, adrenocorticotropic hormone, and corticosterone from the hypothalamus was tested. In the hippocampus and prefrontal cortex, concentrations of 5-HT and its metabolite 5-hydroxyindoleacetic acid, as well as monoamine oxidase A, glucocorticoid receptor, and 5-HT1A receptor expression levels, were measured. Furthermore, we examined protein and mRNA expression of cAMP-PKA-CREB-BDNF pathway components. The results showed that JYHH had a significant preventative effect on the anxiety-like behaviour induced by CRS and prevented abnormal changes in the HPA axis and 5-HT system. Furthermore, CRS inhibited the cAMP-PKA-CREB-BDNF pathway, which returned to normal levels following JYHH treatment. This might be the underlying molecular mechanism of the antianxiety effect of JYHH, which could provide a new clinical target for preventative anxiolytic drugs for chronic stress.

show abstract

“…Epidemiological data indicates that global prevalence of anxiety disorders reaches 7.3% (95% CI 4.8–10.9%) [ 1 , 2 , 3 ]. For example, in the USA and China, the lifetime prevalence of generalized anxiety disorders is 6.2% and 4.7%, panic attacks 5.2% and 3.4%, and obsessive-compulsive disorders 2.7% and 3.2%, respectively [ 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

“…However, they still remain in medical practice [ 13 ]. Later, these tranquilizers were replaced by selective serotonin reuptake inhibitors (SSRIs) [ 2 ]. Use of benzodiazepine tranquilizers is limited due to their sedative and muscle relaxant effects as well as ataxia and impaired cognitive functions [ 14 ], which appear simultaneously with anxiolytic effects [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

“…One of the SSRIs’ disadvantages is their relatively long latency period before the emergence of the anxiolytic effect [ 17 ]. It is noted that approximately 40% of patients are nonresponsive to SSRIs and serotonin-noradrenaline reuptake inhibitors (SNRIs) [ 18 ], anxiolytic effects of which range from mild to moderate (effect sizes 0.37–0.44) [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Involvement of Chaperone Sigma1R in the Anxiolytic Effect of Fabomotizole

Voronin

Vakhitova

Tsypysheva

et al. 2021

IJMS

View full text Add to dashboard Cite

Sigma-1 receptor (chaperone Sigma1R) is an intracellular protein with chaperone functions, which is expressed in various organs, including the brain. Sigma1R participates in the regulation of physiological mechanisms of anxiety (Su, T. P. et al., 2016) and reactions to emotional stress (Hayashi, T., 2015). In 2006, fabomotizole (ethoxy-2-[2-(morpholino)-ethylthio]benzimidazole dihydrochloride) was registered in Russia as an anxiolytic (Seredenin S. and Voronin M., 2009). The molecular targets of fabomotizole are Sigma1R, NRH: quinone reductase 2 (NQO2), and monoamine oxidase A (MAO-A) (Seredenin S. and Voronin M., 2009). The current study aimed to clarify the dependence of fabomotizole anxiolytic action on its interaction with Sigma1R and perform a docking analysis of fabomotizole interaction with Sigma1R. An elevated plus maze (EPM) test revealed that the anxiolytic-like effect of fabomotizole (2.5 mg/kg i.p.) administered to male BALB/c mice 30 min prior EPM exposition was blocked by Sigma1R antagonists BD-1047 (1.0 mg/kg i.p.) and NE-100 (1.0 mg/kg i.p.) pretreatment. Results of initial in silico study showed that fabomotizole locates in the active center of Sigma1R, reproducing the interactions with the site’s amino acids common for established Sigma1R ligands, with the ΔGbind value closer to that of agonist (+)-pentazocine in the 6DK1 binding site.

show abstract

Anxiety disorders

Cited by 364 publications

References 137 publications

Correlates of Quality of Life in Anxiety Disorders: Review of Recent Research

Correlates of Quality of Life in Anxiety Disorders: Review of Recent Research

Jie‐Yu‐He‐Huan Capsule Ameliorates Anxiety‐Like Behaviours in Rats Exposed to Chronic Restraint Stress via the cAMP/PKA/CREB/BDNF Signalling Pathway

Involvement of Chaperone Sigma1R in the Anxiolytic Effect of Fabomotizole

Contact Info

Product

Resources

About